Illumina, Inc. (NASDAQ:ILMN) stock rose 0.78% (As on August 10, 11:24:18 AM UTC-4, Source: Google Finance) after the company cut annual profit forecast, in a sign that a funding crunch among its biotech and pharmaceutical clients is expected to weigh on sales for its genetic testing tools and diagnostics products. Core Illumina revenues were flat year over year (up 2% at the constant exchange rate or CER) to $1.16 billion. Core Illumina Sequencing Consumable revenues totaled $739 million in the reported quarter, down 1% year over year. The model projected Core Illumina revenues of $1.18 billion for Q2. Sequencing Instrument revenues for Core Illumina of $193 million grew 2% year over year. The increase was partially led by strength in NovaSeq X shipments. Core Illumina sequencing service and other revenues were $134 million (up 7% year over year). Higher instrument service contract revenues drove the upside on a growing installed base. GRAIL contributed $22 million to revenues during the reported quarter compared with $12 million in the year-ago period.

ILMN in the second quarter of FY 23 has reported the adjusted earnings per share of 32 cents, beating the analysts’ estimates for the adjusted earnings per share of 2 cents, according to the Zacks Consensus Estimate. The company had reported the adjusted revenue growth of 2 percent to $1.18 billion in the second quarter of FY 23, beating the analysts’ estimates for revenue by 1.1%. The adjusted gross margin (excluding amortization of acquired intangible assets) was 66.3% in the reported quarter, highlighting a contraction of 312 basis points (bps) year over year. The decline is attributed to lower fixed-cost leverage on reduced manufacturing volumes and lower instrument margins due to the NovaSeq X launch, as expected for a new platform introduction. Illumina exited the second quarter of 2023 with cash and cash equivalents plus short-term investments of $1.56 billion compared with $1.55 billion at the end of first-quarter 2023.

llumina expects full-year adjusted profit per share to be between $0.75 and $0.90, compared with its prior forecast of $1.25 to $1.50. The outlook reflects a tax expense impact of about $75 million. The company expects the second-half revenue to be negatively impacted by customers remaining more cautious in their purchasing, a more protracted recovery in China, and a larger-than-expected temporary decline in high throughput consumables as customers transition to NovaSeq X.